Sugi Predict

Sugi Predict / Compounds / SCHEMBL30141845

SCHEMBL30141845

SCHEMBL30141845

CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 2/20 0.68
▸ C5AR1 P21730 2/20 0.62
▸ CALCR P30988 4/20 0.59
▸ KDM1A O60341 3/20 0.57
▸ F2 P00734 2/20 0.56
▸ MAOB P27338 1/20 0.55
▸ KDM5A P29375 1/20 0.55
▸ KDM1B Q8NB78 1/20 0.55
▸ GHSR Q92847 1/20 0.55
▸ TFPI P10646 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29749731 0.99 APLNR (0.68) APLNRC5AR1CALCRKDM1AF2
SCHEMBL29700297 0.97 APLNR (0.66) APLNRC5AR1CALCRKDM1AF2
SCHEMBL30712933 0.92 C5AR1 (0.62) APLNRC5AR1CALCRKDM1AMAOB
SCHEMBL31182976 0.91 CALCR (0.70) APLNRCALCRF2
SCHEMBL29903338 0.90 F2 (0.62) APLNRCALCRF2GHSR
SCHEMBL31691514 0.89 APLNR (0.62) APLNRC5AR1CALCRF2
SCHEMBL31307221 0.89 C5AR1 (0.57) APLNRC5AR1CALCR
SCHEMBL30437321 0.89 APLNR (0.66) APLNRC5AR1CALCRKDM1ATFPI
SCHEMBL31167611 0.89 CALCR (0.71) C5AR1CALCRF2TFPI
SCHEMBL29377908 0.89 C5AR1 (0.63) APLNRC5AR1CALCRKDM1AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240358843-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF COHERENT BIOPHARMA SUZHOU LTD (CN) 2024-10-31 — — US disclosed
EP-4360654-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF Coherent Biopharma (Suzhou), Limited (CN) 2024-05-01 — — EP disclosed
WO-2022268202-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF 同宜医药（苏州）有限公司 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358843-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SELPLG, SELL, SIGLEC7 APLNR 247/4885C5AR1 145/4885CALCR 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback